Electrochemical characterization of repaglinide and its determination in human plasma using liquid chromatography with dual-channel coulometric detection

被引:9
作者
Jirovsky, David [1 ]
Bartosova, Zdenka [1 ]
Skopalova, Jana [1 ]
Maier, Vitezslav [1 ]
机构
[1] Palacky Univ, Dept Analyt Chem, CZ-77146 Olomouc, Czech Republic
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2010年 / 878卷 / 31期
关键词
Repaglinide; Rosiglitazone; HPLC; Coulometric detection; Peroral antidiabetics; Plasma; TYPE-2; DIABETES-MELLITUS; ANTIDIABETIC AGENT; HPLC; PHARMACOKINETICS; BIOAVAILABILITY; ROSIGLITAZONE; IONIZATION; MANAGEMENT; DRUGS; ARRAY;
D O I
10.1016/j.jchromb.2010.09.029
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple fast and sensitive HPLC method employing dual-channel coulometric detection for the determination of repaglinide in human plasma is presented The assay involved extraction of repaglinide by ethyl acetate and isocratic reversed-phase liquid chromatography with dual-channel coulometric detection The mobile phase composition was 50mM disodium hydrogen phosphate/acetonitrile (60 40 v/v) pH of the mobile phase 7 5 set up with phosphoric acid For all analyses the first cell working potential was +380 mV the second was +750 mV (vs Pd/H-2) Calibration curve was linear over the concentration range of 5-500 nmol L-1 Rosiglitazone was used as an internal standard The limit of detection CLOD) was established at 28 nmol L-1 and the lower limit of quantification (LLOQ) at 85 nmol L-1 The developed method was applied to human plasma samples spiked with repaglinide at therapeutical concentrations It was confirmed that the method is suitable for pharmacokinetic studies or therapeutic monitoring (C) 2010 Elsevier B V All rights reserved
引用
收藏
页码:3243 / 3248
页数:6
相关论文
共 26 条
  • [1] Acworth IN, 1996, AM LAB, V28, P33
  • [2] Ambavane V, 2002, J Postgrad Med, V48, P246
  • [3] [Anonymous], INT C HARMONISATION
  • [4] [Anonymous], DIAB ATL
  • [5] Electrochemical determination of the antidiabetic drug repaglinide
    El-Ries, Mohamed Abdel Nabi
    Mohamed, Gehad Genidy
    Attia, Ali Kamal
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2008, 128 (01): : 171 - 177
  • [6] QUANTITATION OF THE NEW HYPOGLYCEMIC AGENT AG-EE 388-ZW IN HUMAN PLASMA BY AUTOMATED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION
    GREISCHEL, A
    BESCHKE, K
    RAPP, H
    ROTH, W
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1991, 568 (01): : 246 - 252
  • [7] Hatorp V, 1998, INT J CLIN PHARM TH, V36, P636
  • [8] Clinical pharmacokinetics and pharmacodynamics of repaglinide
    Hatorp, V
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (07) : 471 - 483
  • [9] Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry
    Ho, ENM
    Yiu, KCH
    Wan, TSM
    Stewart, BD
    Watkins, KL
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 811 (01): : 65 - 73
  • [10] Defining the role of repaglinide in the management of type 2 diabetes mellitus - A review
    Johansen, Odd Erik
    Birkelan, Kare L.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (05) : 319 - 335